Rifabutin-Containing Triple Therapy (RHB-105) for Eradication of Helicobacter pylori: Randomized ERADICATE Hp Trial

Due to increasing resistance to commonly used antibiotics, the World Health Organization and Food and Drug Administration have advocated the development of new therapeutic regimens for Helicobacter pylori (H. pylori). This phase three, double-blind study (ERADICATE Hp) randomized (2:1) treatment-naï...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Antibiotics (Basel) 2020-10, Vol.9 (10), p.685
Hauptverfasser:	Kalfus, Ira N., Graham, David Y., Riff, Dennis S., Panas, Raymond M.
Format:	Artikel
Sprache:	eng
Schlagworte:	Amoxicillin Antibiotics Antimicrobial agents clinical trial Diarrhea Dosage and administration Drug dosages Drug resistance Dyspepsia Eradication Gastric cancer Helicobacter pylori Infections Leukopenia Nausea Omeprazole Patient outcomes Placebos Population Prevention RHB-105 Rifabutin Sensitivity analysis standard-of-care Therapy Vomiting
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!